Figures & data
Table 1. Demographic characteristics, known chronic diseases and drug usage for AKI and no AKI groups at the time of admission.
Table 2. Length of stay and outcome.
Figure 1. Distribution of urine NGAL (ng/mL) levels and the median NGAL (ng/mL) levels in AKI and no AKI groups. NGAL, neutrophil gelatinase associated lipocalin; AKI, acute kidney injury.
Figure 2. ROC analysis for urine NGAL (ng/mL) levels with regard to presence or absence of AKI. NGAL, neutrophil gelatinase associated lipocalin; AKI, acute kidney injury.
Figure 3. Mean intravenous furosemide doses at the first, second and third day of hospitalization for AKI and no AKI groups. AKI, acute kidney injury.
